Bliss GVS Pharma reports strong half-year financials, makes key legal appointment

Bliss GVS Pharma Ltd. reported significant financial performance for the half-year ended September 30, 2025. Consolidated revenue from operations reached INR 45,186.77 lakh, with total comprehensive income attributable to owners of the company at INR 7,115.92 lakh. Diluted earnings per share for the half-year were INR 6.58. The standalone results show revenue from operations at INR 35,358.96 lakh and total comprehensive income of INR 4,578.52 lakh.

In a key management development, Shreekrushna Joshi has been appointed as head – legal, effective November 6, 2025. Joshi brings over 15 years of experience in corporate legal, contract management, and secretarial compliance, including prior roles at Mahindra & Mahindra, Mankind Pharma, Sun Pharma Advanced Research Company, and RPG Life Sciences. The board also approved the sale of a 51% stake in its step-down subsidiary, Greenlife Bliss Healthcare Ltd., Nigeria, for $1,300,000, effective April 1, 2025, resulting in its deconsolidation.

The company's cash flow statement highlights net cash generated from operating activities of INR 7,755.21 lakh on a consolidated basis for the half-year ended September 30, 2025. The company also allotted 279,200 equity shares upon the exercise of stock options by employees. As of September 30, 2025, 1,940,250 options remain outstanding.